BPI-9016M | c-Met/AXL Inhibitor

Cas No.:	1528546-94-2
Formula:	C₂₅H₁₈F₂N₄O₃
M.Wt:	460.43
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

MSDS

COA

Cat. No.	Product name	Field of application
DC46949	Terevalefim	Terevalefim (ANG-3777), an hepatocyte growth factor (HGF) mimetic, selectively activates the c-Met receptor.
DC46948	Gemnelatinib	Gemnelatinib is a tyrosine kinase inhibitor (WO2018077227, implementation example 1). Gemnelatinib can be used for the research of cancer.
DC46947	Fosgonimeton	Fosgonimeton is a hepatocyte growth factor receptor agonist (WO2017210489).
DC44838	Norleual	Norleual is an angiotensin IV analog. Norleual is a highly potent HGF/c-MET inhibitor (IC50=3 pM). Norleual inhibits HGF-induced MDCK cell proliferation and invasion in vitro. Norleual also is an AT4 receptor antagonist; disrupts LTP stabilization. Antiangiogenic.
DC39099	Ningetinib	Ningetinib is a potent, orally bioavailable inhibitor of tyrosine kinase with IC50 of 6.7 nM, 1.9 nM and <1.0 nM for c-Met, VEGFR2 and Axl, respectively. Ningetinib exhibits antitumor activity.
DC28340	BPI-9016M	BPI-9016M is a potent, orally active, and selective dual c-Met and AXL tyrosine kinases inhibitor. BPI-9016M suppresses tumor cell growth, migration and invasion of lung adenocarcinoma.
DC8515	BMS-2	BMS-2 is a potent MET kinase inhibitor with an IC50 value of 1.8nM. It also possesses potent inhibitory activity against Flt-3 and VEGFR-2 kinases, IC50 values of 4nM and 27nM respectively.
DC12007	SOMG-833	A potent, selective, ATP-competitive c-MET inhibitor with IC50 of 0.93 nM.